DEERFIELD MANAGEMENT COMPANY, L.P.
CIK 1009258 · last filed 2026-07-17
DEERFIELD MANAGEMENT COMPANY, L.P. is a corporate insider who has filed 76 SEC Form 4 insider transactions across 40 companies since 2007. The most recent filing, for NUVL, was dated Jul 17, 2026. Across all open-market trades the lifetime net is +$556.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $489.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$489.87M
Companies
40
Total Filings
76
Lifetime Open-Market Net
$556.91M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NUVL | Director | 0 | $123.96 | $0 | $0 | 6 | 2026-07-17 |
| PBLS | 10%+ Owner | 533,220 | — | — | $0 | 1 | 2026-06-11 |
| LRMR | Director | — | $3.83 | — | $0 | 7 | 2026-05-20 |
| PHGE | Director | 65,634 | $0.18 | $12.0K | $0 | 2 | 2025-04-18 |
| SPRY | 10%+ Owner | 5,257,329 | $5.67 | $29.81M | -$60.86M | 1 | 2024-11-13 |
| BiomX Inc. (PHGE.U) Delisted | Director | 3,055,049 | $0.90 | $2.75M | $0 | 2 | 2024-07-15 |
| Acutus Medical, Inc. (AFIB) Delisted | Director | 1,026,243 | $0.09 | $92.4K | $252.00M | 4 | 2023-06-20 |
| CareMax, Inc. (CMAXW) Delisted | Director | — | $0.01 | — | $0 | 2 | 2023-06-12 |
| TOI | 10%+ Owner | 1,605,477 | $4.95 | $7.95M | $0 | 1 | 2021-11-16 |
| Oncology Institute, Inc. (DFPHU) Delisted | Director | 2,500,000 | $10.26 | $25.65M | $0 | 1 | 2020-03-17 |
| BDTX | 10%+ Owner | 778,790 | $1.76 | $1.37M | $30.40M | 1 | 2020-02-03 |
| MIRM | 10%+ Owner | 1,558,456 | $112.23 | $174.91M | $39.84M | 1 | 2019-07-24 |
| ACRS | 10%+ Owner | 1,072,775 | $5.33 | $5.72M | -$38.4K | 2 | 2019-06-26 |
| Q32 Bio Inc. (FIXX) Delisted | Director | 7,150 | $16.82 | $120.3K | $96.00M | 2 | 2019-04-15 |
| AERIE PHARMACEUTICALS INC (AERI) Delisted | 10%+ Owner | 2,675,638 | $15.25 | $40.80M | $0 | 1 | 2018-07-23 |
| PRTO | Director | — | $27.04 | — | $0 | 1 | 2018-06-12 |
| KNSA | 10%+ Owner | 843,352 | $79.44 | $67.00M | $79.98M | 1 | 2018-05-31 |
| AdaptHealth Corp. (VTL) Delisted | Director | 62,500 | — | — | $0 | 1 | 2018-04-04 |
| CAS MEDICAL SYSTEMS INC (CASM) Delisted | 10%+ Owner | 2,947,554 | — | — | -$3.72M | 1 | 2017-01-26 |
| Invuity, Inc. (IVTY) Delisted | 10%+ Owner | 1,807,239 | — | — | -$4.60M | 1 | 2016-12-14 |
| VNDA | 10%+ Owner | 2,660,207 | $5.16 | $13.73M | $42.54M | 4 | 2016-09-19 |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | Director | — | — | — | $0 | 1 | 2016-09-14 |
| AXGN | 10%+ Owner | 3,102,136 | $41.15 | $127.65M | -$10.29M | 2 | 2016-07-18 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | 10%+ Owner | 62,857 | $0.00 | $25 | $30.00M | 1 | 2016-07-06 |
| XENOPORT INC (XNPT) Delisted | 10%+ Owner | 6,667,391 | — | — | $418.2K | 1 | 2016-02-23 |
| AveXis, Inc. (AVXS) Delisted | 10%+ Owner | 249,909 | — | — | $116.84M | 1 | 2016-02-19 |
| ANTARES PHARMA, INC. (ATRS) Delisted | 10%+ Owner | 7,818,639 | $5.59 | $43.71M | -$7.29M | 2 | 2015-07-21 |
| LIFE | 10%+ Owner | 18,269 | $18.80 | $343.5K | $4.20M | 1 | 2015-05-13 |
| Invitae Corp (NVTA) Delisted | 10%+ Owner | 48,388 | $0.09 | $4.3K | $11.20M | 1 | 2015-02-19 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | — | — | — | $0 | 1 | 2014-09-25 |
| MEDICINES CO /DE (MDCO) Delisted | 10%+ Owner | 2,454,261 | — | — | -$34.90M | 1 | 2011-04-06 |
| NxStage Medical, Inc. (NXTM) Delisted | 10%+ Owner | 875,072 | — | — | -$14.65M | 2 | 2009-10-13 |
| SALIX PHARMACEUTICALS LTD (SLXP) Delisted | 10%+ Owner | 2,186,025 | — | — | $2.26M | 3 | 2009-07-29 |
| DUSA | 10%+ Owner | 1,064,317 | $57.68 | $61.39M | $1.90M | 1 | 2009-06-26 |
| PAR PHARMACEUTICAL COMPANIES, INC. (PRX) Delisted | 10%+ Owner | 1,357,068 | — | — | -$7.25M | 1 | 2008-12-01 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | 10%+ Owner | 493,713 | — | — | -$7.02M | 1 | 2008-10-21 |
| NITROMED INC (NTMD) Delisted | 10%+ Owner | 3,406,117 | — | — | $1.38M | 3 | 2008-07-15 |
| ARENA PHARMACEUTICALS INC (ARNA) Delisted | 10%+ Owner | 186,174 | $99.99 | $18.62M | -$1.31M | 1 | 2007-10-23 |
| VIA Pharmaceuticals, Inc. (VIAP) Delisted | 10%+ Owner | 1,296,399 | — | — | -$127.5K | 1 | 2007-10-19 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | 10%+ Owner | — | $15.50 | — | $0 | 1 | 2007-07-23 |
Recent Filings
76 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-17 | NUVL | Mixed | −138,097,488 | -$17.12B | EDGAR |
| 2026-06-18 | NUVL | Grant (A) | +6,888 | $0 | EDGAR |
| 2026-06-11 | PBLS | Conv (C) | +11,284,224 | $0 | EDGAR |
| 2026-05-20 | LRMR | Grant (A) | — | $0 | EDGAR |
| 2025-06-20 | NUVL | Grant (A) | +10,588 | $0 | EDGAR |
| 2025-05-15 | LRMR | Grant (A) | — | $0 | EDGAR |
| 2025-04-18 | PHGE | Grant (A) | — | $0 | EDGAR |
| 2025-03-03 | PHGE | Mixed | +4,238,988 | $3.94M | EDGAR |
| 2025-01-28 | — | Disp (D) | — | $0 | |
| 2024-11-13 | SPRY | Sell (S) | −3,379,620 | -$60.86M | EDGAR |
Showing 1–10 of 76
Page 1 of 8
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.